Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Novartis

Status and phase: Completed; Phase 3

Conditions: Vascular Dementia

Treatments: Drug: Rivastigmine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00099216

CENA713BIA05

Details and patient eligibility

About

The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Enrollment: 708 patients

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Between the ages of 50 and 85 years old
• Have contact with a responsible caregiver 3 or more days per week
• Be male or a female who is surgically sterilized or one year post menopausal

Exclusion criteria

• Current diagnosis of severe or unstable cardiovascular or other diseases
• Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind